¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Çѱ¹À¯¹æ¾ÏÇÐȸ 2022 Ãß°èÇмú´ëȸ : 2022-10-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Çѱ¹À¯¹æ¾ÏÇÐȸ 2022 Ãß°èÇмú´ëȸ : 2022-10-15
±³À°ÀÏÀÚ : 2022-10-15
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 4Ãþ ÄÁº¥¼ÇȦ  
±³À°ÁÖÁ¦ : 2022 Ãß°èÇмú´ëȸ
ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : Á¤Áö¿µ
¿¬¶ôó : 02-3461-6060  
À̸ÞÀÏ : kbcs@kbcs.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú      
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 11 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í Á¤È¸¿ø. ÁØȸ¿ø 60,000¿ø Àü°øÀÇ.°£È£»ç 30,000¿ø ºñȸ¿ø 80,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 09:10~09:40 HER2 heterogeneity and HER2-low breast cancer  ¿øÇý¼º(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 09:40~10:10 Updates of adjuvant/neoadjuvant therapy in HER2+ non-metastatic breast cancer  À̽¾Æ(Â÷ÀÇ°úÇдë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 10:10~10:40 Updates of metastatic HER2+ breast cancer treatment  ±ÇÁ¤Çý(Ãæ³²ÀÇ´ë) 
È޽Ġ10-15  10:40~11:00 Break  () 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 11:00~11:30 Optimal management and duration in ER-low breast cancer  Á¤¼ºÀÇ(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 11:30~12:00 Which CDK 4/6 inhibitor with endocrine therapy in high-risk HR+ breast cancer  ¹è¼ö¿¬(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 12:00~12:30 Updates of metastatic HR+/HER2- breast cancer treatment  ¾ç¿¹¿ø(ÃæºÏÀÇ´ë) 
½Ä»ç 10-15  12:30~13:30 ÀÓ½ÃÃÑȸ ¹× LUNCH  () 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 13:30~14:00 Potential biomarkers in TNBC  ¾È¼º±Í(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 14:00~14:30 Updates of adjuvant/neoadjuvant therapy in non-metastatic TNBC  ÃÖÁ¤Àº(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 14:30~15:00 Updates of metastatic TNBC treatment  °í¼öÁø(¿ï»êÀÇ´ë) 
È޽Ġ10-15  15:00~15:20 Break  () 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 15:20~15:50 Breast cancer screening based on risk assessment: time to update KBCS guidelines?  ¹é¼ö¿¬(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 15:50~16:15 Adjuvant treatment with bisphosphonates and other bone-modifying agents: updated ASCO guideline in breast cancer  ±èÁö¼±(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ A 16:15~16:40 Practically coping with side effects of CDK 4/6 inhibitor and dose adjustment  ¹ÚÈñ¼º(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 09:10~09:40 De-escalation of breast surgery in patients with predicted pCR after neoadjuvant chemotherapy  °û¼ºÂù(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 09:40~10:10 Omitting axillary sentinel lymph node biopsy following neoadjuvant chemotherapy  À¯Àç¹Î(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 10:10~10:40 Optimal regional nodal irradiation following breast surgery in N1 disease  À̼±¿µ(ÀüºÏÀÇ´ë) 
È޽Ġ10-15  10:40~11:00 Break  () 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 11:00~11:15 À¯¹æ¾Ï ºÐ¾ß¿¡¼­ ȯÀÚÁ᫐ Àӻ󿬱¸ÀÇ Çʿ伺 ¹× ÇöȲ  Çã´ë¼®(PACEN»ç¾÷´Ü) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 11:15~11:30 ÃÊÀ½ÆÄ°Ë»ç ÈÄ ÀÓ»ó ¸²ÇÁÀý À½¼ºÀÎ À¯¹æ¾ÏȯÀÚ¿¡¼­ ¾×¿Í¼ö¼ú »ý·«ÀÇ ¾ÈÀü¼º¿¡ °üÇÑ ÀüÇâÀû, ´Ù±â°ü, 3»ó ÀÓ»ó½ÃÇè  ÇÑ¿ø½Ä(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 11:30~11:45 ÀþÀº À¯¹æ¾Ï ȯÀÚ¿¡¼­ °¡ÀÓ·Â º¸Á¸À» À§ÇÑ ´ÙÇÐÁ¦ °øµ¿ ÀÇ»ç °áÁ¤  ±èÈñÁ¤(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 11:45~12:00 Ãʱâ À¯¹æ¾ÏȯÀÚ¿¡¼­ ÃßÀû °üÂû°Ë»ç¹ýÀÇ ÃÖÀûÈ­ ¿¬±¸  ¹®Çü°ï(¼­¿ïÀÇ´ë) 
Åä·Ð 10-15 ÄÁº¥¼ÇȦ B 12:00~12:30 Panel discussion: À¯¹æ¾Ï ºÐ¾ß ȯÀÚÁ᫐ Àӻ󿬱¸ÀÇ °³¼± ¹× ¹ßÀü¹æÇâ  ±è¹ÎÁ¤¿Ü4ÀÎ(PACEN ¿Ü) 
½Ä»ç 10-15  12:30~13:30 ÀÓ½ÃÃÑȸ ¹× LUNCH  () 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 13:30~14:00 Application of 3D printing technique in breast surgery  °í¹ü¼®(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 14:00~14:30 ICG-hyaluronic acid injection for non-palpable breast lesion localization  ½ÅÇõÀç(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 14:30~15:00 Surgical experiences in breast disease management  ±è¿¹Á¤(ÀüÁÖ¿¹¼öº´¿ø) 
È޽Ġ10-15  15:00~15:20 Break  () 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 15:20~15:40 Neoadjuvant chemotherapy  Á¤ÀçÇÐ(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 15:40~16:00 Surgical treatment  ¹ÎÁØ¿ø(´Ü±¹ÀÇ´ë) 
±³À°½Ã°£ 10-15 ÄÁº¥¼ÇȦ B 16:00~16:20 Metastatic breast cancer  °­»óÀ²(ÀüºÏÀÇ´ë) 
Åä·Ð 10-15 ÄÁº¥¼ÇȦ B 16:20~16:40 Panel discussion  ¹Ú¿µ»ï¿Ü2ÀÎ(ÀüÁÖ¿¹¼öº´¿ø ¿Ü) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Çѱ¹À¯¹æ¾ÏÇÐȸ 2022 Ãß°èÇмú´ëȸ : 2022-10-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °­¸ª¾Æ»êº´¿ø ´ëÇÑ´ç´¢º´ÇÐȸ °­¿øÁöȸ Á¦12ȸ ¿¬¼ö°­Á : 2022-10-15
´ÙÀ½±Û (¿Â¶óÀÎ) ¼¼ºê¶õ½ºº´¿ø ÃÊÀ½ÆÄ ¹× °£¼¶À¯È­°Ë»ç ¿öÅ©¼¥ : 2022-10-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20820 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ – Á¦31ȸ °³¿øÀǸ¦ À§ÇÑ ¿¬¼ö°­Á : 2024-06-16 0 6 2024-05-27
20819 ºÎ»ê ´ëÇÑÀ̽ÄÇÐȸ 2024³â ½ÅÀåÀÌ½Ä ½ÉÆ÷Áö¾ö : 2024-06-16 0 4 2024-05-27
20818 Á¦ÁÖ ´ëÇѳ»ºÐºñÇÐȸ Á¦22ȸ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-16 0 5 2024-05-27
20817 ¼­¿ï ¼Ò¾Æû¼Ò³âÇൿ¹ß´ÞÁõÁø ¾ð¾î°Ë»ç ÇÁ·Î±×·¥ ¿öÅ©¼ó : 2024-06-16 0 4 2024-05-27
20816 ¼­¿ï Á¦28ȸ ¼­¿ï½Ã³»°úÀÇ»çȸ Á¤±âÃÑȸ ¹× Çмú´ëȸ : 2024-06-16 0 15 2024-05-27
20815 ¼­¿ï 2024³â Á¦16ȸ °æÈñ´ëÇб³º´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-16 0 16 2024-05-27
20814 ºÎ»ê 2024 ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿µ³²¼Ò¾Æ¾Ë·¹¸£±â ½ÉÆ÷Áö¿ò : 2024-06-16 0 4 2024-05-27
20813 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦23Â÷ ½Å»ý¾Æ¼Ò»ý¼ú workshop : 2024-06-16 0 21 2024-05-27
20812 ¼­¿ï 2024³â ´ëÇÑÀÇÇÐÀ¯ÀüÇÐȸ ÀÇÇÐÀ¯ÀüÇÐ Primer Course : 2024-06-16 0 40 2024-05-27
20811 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 26 2024-05-27
20810 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°ú ÄÄÇ»Åͼö¼úÇÐȸ - Á¦3ȸ ±¹Á¦ ·Îº¿¼ö¼ú ½ÉÆ÷Áö¾ö : 2024-06-15 0 6 2024-05-27
20809 °æ±â ´ëÇѺñ¸¸ÇÐȸ Á¦18ȸ ODOT (One Day Course of Obesity Treatment) : 2024-06-15 0 5 2024-05-27
20808 ¼­¿ï 2024³â Á¦ 1ȸ ºñ¸¸ ¿¬¼ö°­ÁÂ(ObesityCare Pro) : 2024-06-15 0 5 2024-05-27
20807 ¼­¿ï 2024 °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ½Å°æ¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-15 0 4 2024-05-27
20806 ¼­¿ï ´ëÇѼöºÎ¿Ü°úÇÐȸ ¼öºÎ»óÁö ÇÏ°èÇмú´ëȸ : 2024-06-15 0 4 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷